Summary
Topical calcineurin inhibitors (TCIs) were developed following research on immunosuppressive drugs used orally for their anti-rejection effect in transplanted patients. They are used as an alternative to topical corticosteroids for the treatment of inflammatory skin diseases. Two products are available on the market:
– Tacrolimus, marketed in France in 2003 under the name Protopic®
– Pimecrolimus, marketed under the name of Elidel® (did not receive marketing authorization in France).
×
N.B. : This limited content is for the general public. If you are a health professional, click here to register for free and gain access to a dedicated deeper content.
If you already have an account, log in!
Therapeutics in Dermatology, Fondation René Touraine © 2001-2016
